for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover The Lancet
  [SJR: 14.638]   [H-I: 600]   [1996 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 0140-6736 - ISSN (Online) 1474-547X
   Published by Elsevier Homepage  [3033 journals]
  • NSAIDs for high-risk patients: none, celecoxib, or naproxen'
    • Authors: Patricia McGettigan; Anne-Marie Schjerning Olsen
      Pages: 2351 - 2352
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Patricia McGettigan, Anne-Marie Schjerning Olsen


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)30980-7
       
  • Bioprosthetic surgical and transcatheter heart valve thrombosis
    • Authors: Jeroen J Bax; Gregg W Stone
      Pages: 2352 - 2354
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Jeroen J Bax, Gregg W Stone


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)30764-x
       
  • Paediatric head imaging decisions are not child's play
    • Authors: William R Mower
      Pages: 2354 - 2355
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): William R Mower


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)30932-7
       
  • Sickle cell disease: tipping the balance of genomic research to catalyse
           discoveries in Africa
    • Authors: Julie Makani; Solomon F Ofori-Acquah; Furahini Tluway; Nicola Mulder; Ambroise Wonkam
      Pages: 2355 - 2358
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Julie Makani, Solomon F Ofori-Acquah, Furahini Tluway, Nicola Mulder, Ambroise Wonkam


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31615-x
       
  • A global research agenda on migration, mobility, and health
    • Authors: Johanna Hanefeld; Jo Vearey; Neil Lunt; Sadie Bell; Karl Blanchet; Diane Duclos; Ludovica Ghilardi; Daniel Horsfall; Natasha Howard; Jo Hunter Adams; Mphatso Kamndaya; Caroline Lynch; Tackson Makandwa; Nuala McGrath; Moeketsi Modesinyane; Kate O'Donnell; Chesmal Siriwardhana; Richard Smith; Adrienne Testa; Kuda Vanyoro; Helen Walls; Kolitha Prabhash Wickramage; Cathy Zimmermann
      Pages: 2358 - 2359
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Johanna Hanefeld, Jo Vearey, Neil Lunt


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31588-x
       
  • Offline: The Donald Trump Promise
    • Authors: Richard Horton
      First page: 2360
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Richard Horton


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31657-4
       
  • Access to abortion in the USA—the legal battle
    • Authors: Gavin Cleaver
      Pages: 2361 - 2362
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Gavin Cleaver


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31663-x
       
  • Preparedness for natural disasters in Colombia
    • Authors: Joe Parkin Daniels
      Pages: 2363 - 2364
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Joe Parkin Daniels


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31664-1
       
  • Hypertension
    • Authors: Richard Barnett
      First page: 2365
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Richard Barnett


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31570-2
       
  • Where do broken hearts go'
    • Authors: Tania Glyde
      First page: 2366
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Tania Glyde


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31571-4
       
  • The art of immunisation
    • Authors: James Smith
      First page: 2367
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): James Smith


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31572-6
       
  • The art of priority setting
    • Authors: Mireille Goetghebeur; Hector Castro-Jaramillo; Rob Baltussen; Norman Daniels
      Pages: 2368 - 2369
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Mireille Goetghebeur, Hector Castro-Jaramillo, Rob Baltussen, Norman Daniels


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31573-8
       
  • Julius Stuart Youngner
    • Authors: Geoff Watts
      First page: 2370
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Geoff Watts


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31574-x
       
  • Exposure to lead in petrol and increased incidence of dementia
    • Authors: Esme Fuller-Thomson; Sydney A Jopling
      First page: 2371
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Esme Fuller-Thomson, Sydney A Jopling


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31464-2
       
  • Exposure to lead in petrol and increased incidence of dementia
    • Authors: Mark A S Laidlaw; Arthur E Poropat; Andy Ball; Howard W Mielke
      Pages: 2371 - 2372
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Mark A S Laidlaw, Arthur E Poropat, Andy Ball, Howard W Mielke


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31466-6
       
  • Exposure to lead in petrol and increased incidence of dementia –
           Authors' reply
    • Authors: Hong Chen; Barry Jessiman; Ray Copes; Paul J Villeneuve; Richard T Burnett
      Pages: 2372 - 2373
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Hong Chen, Barry Jessiman, Ray Copes, Paul J Villeneuve, Richard T Burnett


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31459-9
       
  • Stroke in ICD-11: the end of a long exile
    • Authors: Raad Shakir; Bo Norrving
      First page: 2373
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Raad Shakir, Bo Norrving


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31567-2
       
  • CONACYT's freeze on postgraduate fellowships in Mexico
    • Pages: 2373 - 2374
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Interinstitutional group of Mexican postgraduate students


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31568-4
       
  • Gastrointestinal safety of celecoxib versus naproxen in patients with
           cardiothrombotic diseases and arthritis after upper gastrointestinal
           bleeding (CONCERN): an industry-independent, double-blind, double-dummy,
           randomised trial
    • Authors: Francis K L Chan; Jessica Y L Ching; Yee Kit Tse; Kelvin Lam; Grace L H Wong; Siew C Ng; Vivian Lee; Kim W L Au; Pui Kuan Cheong; Bing Y Suen; Heyson Chan; Ka Man Kee; Angeline Lo; Vincent W S Wong; Justin C Y Wu; Moe H Kyaw
      Pages: 2375 - 2382
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Francis K L Chan, Jessica Y L Ching, Yee Kit Tse, Kelvin Lam, Grace L H Wong, Siew C Ng, Vivian Lee, Kim W L Au, Pui Kuan Cheong, Bing Y Suen, Heyson Chan, Ka Man Kee, Angeline Lo, Vincent W S Wong, Justin C Y Wu, Moe H Kyaw
      Background Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require non-steroidal anti-inflammatory drugs (NSAIDs). We hypothesised that a cyclooxygenase-2-selective NSAID plus proton-pump inhibitor is superior to a non-selective NSAID plus proton-pump inhibitor for prevention of recurrent ulcer bleeding in concomitant users of aspirin with previous ulcer bleeding. Methods For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin. After ulcer healing, an independent staff member randomly assigned (1:1) patients who were negative for Helicobacter pylori with a computer-generated list of random numbers to receive oral administrations of either celecoxib 100 mg twice per day plus esomeprazole 20 mg once per day or naproxen 500 mg twice per day plus esomeprazole 20 mg once per day for 18 months. All patients resumed aspirin 80 mg once per day. Both patients and investigators were masked to their treatments. The primary endpoint was recurrent upper gastrointestinal bleeding within 18 months. The primary endpoint and secondary safety endpoints were analysed in the modified intention-to-treat population. This study was registered with ClinicalTrials.gov, number NCT00153660. Findings Between May 24, 2005, and Nov 28, 2012, we enrolled 514 patients, assigning 257 patients to each study group, all of whom were included in the intention-to-treat population. Recurrent upper gastrointestinal bleeding occurred in 14 patients in the celecoxib group (nine gastric ulcers and five duodenal ulcers) and 31 patients in the naproxen group (25 gastric ulcers, three duodenal ulcers, one gastric ulcer and duodenal ulcer, and two bleeding erosions). The cumulative incidence of recurrent bleeding in 18 months was 5·6% (95% CI 3·3–9·2) in the celecoxib group and 12·3% (8·8–17·1) in the naproxen group (p=0·008; crude hazard ratio 0·44, 95% CI 0·23–0·82; p=0·010). Excluding patients who reached study endpoints, 21 (8%) patients in the celecoxib group and 17 (7%) patients in the naproxen group had adverse events leading to discontinuation of treatment. No treatment-related deaths occurred during the study. Interpretation In patients at high risk of both cardiovascular and gastrointestinal events who require concomitant aspirin and NSAID, celecoxib plus proton-pump inhibitor is the preferred treatment to reduce the risk of recurrent upper gastrointestinal bleeding. Naproxen should be avoided despite its perceived cardiovascular safety. Funding The Research Grant Council of Hong Kong.

      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)30981-9
       
  • Advances in the treatment of advanced oestrogen-receptor-positive breast
           cancer
    • Authors: Nicholas C Turner; Patrick Neven; Sibylle Loibl; Fabrice Andre
      Pages: 2403 - 2414
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Nicholas C Turner, Patrick Neven, Sibylle Loibl, Fabrice Andre
      Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development of resistance to therapy is inevitable in advanced cancer. Major progress has been made in identifying the drivers of oestrogen-receptor-positive breast cancer and the mechanisms of resistance to endocrine therapy. This progress has translated into major advances in the treatment of advanced breast cancer, with several targeted therapies that enhance the efficacy of endocrine therapy; inhibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4 and CDK6 substantially improve progression-free survival. A new wave of targeted therapies is being developed, including inhibitors of PI3K, AKT, and HER2, and a new generation of oestrogen-receptor degraders. Considerable challenges remain in patient selection, deciding on the most appropriate order in which to administer therapies, and establishing whether cross-resistance occurs between therapies.

      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(16)32419-9
       
  • HER2-positive breast cancer
    • Authors: Sibylle Loibl; Luca Gianni
      Pages: 2415 - 2429
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Sibylle Loibl, Luca Gianni
      Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of this disease. This Series article reviews the main achievements so far in the treatment of both metastatic and early HER2-positive breast cancer. The success of neoadjuvant therapy in HER2-positive early breast cancer is especially acknowledged, as pertuzumab has been approved on the basis of a higher proportion of patients achieving a pathological complete response with pertuzumab and trastuzumab than with trastuzumab alone in a neoadjuvant study. Event-free survival after the confirmatory adjuvant trial completed recruitment was numerically better with pertuzumab plus trastuzumab than with trastuzumab alone. With survival rates of almost 5 years in women with metastatic HER2-positive breast cancer and 75% of patients achieving a pathological complete response, new treatments in the past decade have clearly improved the prognosis of HER2-positive breast cancer. Despite these achievements, however, the persisting high toll of deaths resulting from HER2-positive breast cancer calls for continued, intensive clinical research of newer therapies and combinations.

      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(16)32417-5
       
  • Molecular alterations in triple-negative breast cancer—the road to
           new treatment strategies
    • Authors: Carsten Denkert; Cornelia Liedtke; Andrew Tutt; Gunter von Minckwitz
      Pages: 2430 - 2442
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): Carsten Denkert, Cornelia Liedtke, Andrew Tutt, Gunter von Minckwitz
      Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different subgroups of triple-negative breast cancer have been identified on the basis of protein expression, mRNA signatures, and genomic alterations. Important elements of triple-negative breast cancer biology include high proliferative activity, an increased immunological infiltrate, a basal-like and a mesenchymal phenotype, and deficiency in homologous recombination, which is in part associated with loss of BRCA1 or BRCA2 function. A minority of triple-negative tumours express luminal markers, such as androgen receptors, and have a lower proliferative activity. These biological subgroups are overlapping and currently cannot be combined into a unified model of triple-negative breast cancer biology. Nevertheless, the molecular analysis of this disease has identified potential options for targeted therapeutic intervention. This has led to promising clinical strategies, including modified chemotherapy approaches targeting the DNA damage response, angiogenesis inhibitors, immune checkpoint inhibitors, or even anti-androgens, all of which are being evaluated in phase 1–3 clinical studies. This Series paper focuses on the most relevant clinical questions, summarises the results of recent clinical trials, and gives an overview of ongoing studies and trial concepts that will lead to a more refined therapy for this tumour type.

      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(16)32454-0
       
  • Dupilumab for atopic dermatitis
    • Authors: Lindsay C Strowd; Steven R Feldman
      Pages: 2265 - 2266
      Abstract: Publication date: 10–16 June 2017
      Source:The Lancet, Volume 389, Issue 10086
      Author(s): Lindsay C Strowd, Steven R Feldman


      PubDate: 2017-06-13T23:39:00Z
      DOI: 10.1016/s0140-6736(17)31192-3
       
  • The switch to infliximab biosimilars
    • Authors: Richard Veselý; Peter Richardson
      Pages: 2266 - 2268
      Abstract: Publication date: 10–16 June 2017
      Source:The Lancet, Volume 389, Issue 10086
      Author(s): Richard Veselý, Peter Richardson


      PubDate: 2017-06-13T23:39:00Z
      DOI: 10.1016/s0140-6736(17)31258-8
       
  • New pathways of treatment for psoriatic arthritis
    • Authors: Philip Mease
      Pages: 2268 - 2270
      Abstract: Publication date: 10–16 June 2017
      Source:The Lancet, Volume 389, Issue 10086
      Author(s): Philip Mease


      PubDate: 2017-06-13T23:39:00Z
      DOI: 10.1016/s0140-6736(17)31427-7
       
  • Offline: Sweden seeks a renaissance in global health
    • Authors: Richard Horton
      First page: 2272
      Abstract: Publication date: 10–16 June 2017
      Source:The Lancet, Volume 389, Issue 10086
      Author(s): Richard Horton


      PubDate: 2017-06-13T23:39:00Z
      DOI: 10.1016/s0140-6736(17)31583-0
       
  • Cyclone Mora devastates south Asia
    • Authors: Dinesh C Sharma
      First page: 2273
      Abstract: Publication date: 10–16 June 2017
      Source:The Lancet, Volume 389, Issue 10086
      Author(s): Dinesh C Sharma


      PubDate: 2017-06-13T23:39:00Z
      DOI: 10.1016/s0140-6736(17)31580-5
       
  • Cholera outbreak in Haiti—from 2010 to today
    • Authors: John Zarocostas
      Pages: 2274 - 2275
      Abstract: Publication date: 10–16 June 2017
      Source:The Lancet, Volume 389, Issue 10086
      Author(s): John Zarocostas


      PubDate: 2017-06-13T23:39:00Z
      DOI: 10.1016/s0140-6736(17)31581-7
       
  • EULAR: Countries unite to fight rheumatic diseases
    • Authors: Rita Rubin
      First page: 2276
      Abstract: Publication date: 10–16 June 2017
      Source:The Lancet, Volume 389, Issue 10086
      Author(s): Rita Rubin


      PubDate: 2017-06-13T23:39:00Z
      DOI: 10.1016/s0140-6736(17)31582-9
       
  • What is a Global Britain'
    • Authors: Lancet
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): The Lancet


      PubDate: 2017-06-19T09:12:57Z
       
  • Breast cancer targeted therapy: successes and challenges
    • Authors: Lancet
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): The Lancet


      PubDate: 2017-06-19T09:12:57Z
       
  • Kenya's nurses strike takes its toll on health-care system
    • Authors: Lancet
      Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087
      Author(s): The Lancet


      PubDate: 2017-06-19T09:12:57Z
       
  • Department of Error
    • Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087


      PubDate: 2017-06-19T09:12:57Z
       
  • Department of Error
    • Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087


      PubDate: 2017-06-19T09:12:57Z
       
  • Department of Error
    • Abstract: Publication date: 17–23 June 2017
      Source:The Lancet, Volume 389, Issue 10087


      PubDate: 2017-06-19T09:12:57Z
       
  • Treating active rheumatoid arthritis with Janus kinase inhibitors
    • Authors: David L Scott; Matt D Stevenson
      Abstract: Publication date: Available online 16 June 2017
      Source:The Lancet
      Author(s): David L Scott, Matt D Stevenson


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31659-8
       
  • Efficacy and safety of tofacitinib monotherapy, tofacitinib with
           methotrexate, and adalimumab with methotrexate in patients with rheumatoid
           arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head,
           randomised controlled trial
    • Authors: Roy Fleischmann; Eduardo Mysler Stephen Hall Alan Kivitz Robert Moots
      Abstract: Publication date: Available online 16 June 2017
      Source:The Lancet
      Author(s): Roy Fleischmann, Eduardo Mysler, Stephen Hall, Alan J Kivitz, Robert J Moots, Zhen Luo, Ryan DeMasi, Koshika Soma, Richard Zhang, Liza Takiya, Svitlana Tatulych, Christopher Mojcik, Sriram Krishnaswami, Sujatha Menon, Josef S Smolen
      Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate. Methods ORAL Strategy was a 1 year, double-blind, phase 3b/4, head-to-head, non-inferiority, randomised controlled trial in patients aged 18 years or older with active rheumatoid arthritis despite methotrexate therapy. Patients were randomly assigned (1:1:1) to receive oral tofacitinib (5 mg twice daily) monotherapy, oral tofacitinib (5 mg twice daily) plus methotrexate, or subcutaneous adalimumab (40 mg every other week) plus methotrexate at 194 centres in 25 countries. Eligible patients received live zoster vaccine at investigators' discretion. The primary endpoint was the proportion of patients who attained an American College of Rheumatology response of at least 50% (ACR50) at month 6 in the full analysis set (patients who were randomly assigned to a group and received at least one dose of the study treatment). Non-inferiority between groups was shown if the lower bound of the 98·34% CI of the difference between comparators was larger than −13·0%. This trial is registered with ClinicalTrials.gov, number NCT02187055. Findings 1146 patients received treatment (384 had tofacitinib monotherapy; 376 had tofacitinib and methotrexate; and 386 had adalimumab and methotrexate). At 6 months, ACR50 response was attained in 147 (38%) of 384 patients with tofacitinib monotherapy, 173 (46%) of 376 patients with tofacitinib and methotrexate, and 169 (44%) of 386 patients with adalimumab and methotrexate. Non-inferiority was declared for tofacitinib and methotrexate versus adalimumab and methotrexate (difference 2% [98·34% CI −6 to 11]) but not for tofacitinib monotherapy versus either adalimumab and methotrexate (−6 [−14 to 3]) or tofacitinib and methotrexate (−8 [−16 to 1]). In total, 23 (6%) of 384 patients receiving tofacitinib monotherapy, 26 (7%) of 376 patients receiving tofacitinib plus methotrexate, and 36 (9%) of 386 patients receiving adalimumab plus methotrexate discontinued due to adverse events. Two (1%) of the 384 patients receiving tofacitinib monotherapy died. No new or unexpected safety issues were reported for either treatment in this study for up to 1 year. Interpretation Tofacitinib and methotrexate combination therapy was non-inferior to adalimumab and methotrexate combination therapy in the treatment of rheumatoid arthritis in patients with an inadequate response to methotrexate in this trial. Tofacitinib monotherapy was not shown to be non-inferior to either combination. Funding Pfizer Inc.

      PubDate: 2017-06-19T09:12:57Z
       
  • Department of Error
    • Abstract: Publication date: Available online 13 June 2017
      Source:The Lancet


      PubDate: 2017-06-19T09:12:57Z
       
  • The need for a complex systems model of evidence for public health
    • Authors: Harry Rutter; Natalie Savona; Ketevan Glonti; Jo Bibby; Steven Cummins; Diane T Finegood; Felix Greaves; Laura Harper; Penelope Hawe; Laurence Moore; Mark Petticrew; Eva Rehfuess; Alan Shiell; James Thomas; Martin White
      Abstract: Publication date: Available online 13 June 2017
      Source:The Lancet
      Author(s): Harry Rutter, Natalie Savona, Ketevan Glonti, Jo Bibby, Steven Cummins, Diane T Finegood, Felix Greaves, Laura Harper, Penelope Hawe, Laurence Moore, Mark Petticrew, Eva Rehfuess, Alan Shiell, James Thomas, Martin White


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31267-9
       
  • Preventing major gastrointestinal bleeding in elderly patients
    • Authors: Hans-Christoph Diener
      Abstract: Publication date: Available online 13 June 2017
      Source:The Lancet
      Author(s): Hans-Christoph Diener


      PubDate: 2017-06-19T09:12:57Z
      DOI: 10.1016/s0140-6736(17)31507-6
       
  • Post-partum depression—a glimpse of light in the darkness?
    • Authors: Ian Jones
      Abstract: Publication date: Available online 12 June 2017
      Source:The Lancet
      Author(s): Ian Jones


      PubDate: 2017-06-13T23:39:00Z
      DOI: 10.1016/s0140-6736(17)31546-5
       
  • A platinum age for rheumatology
    • Authors: Lancet
      Abstract: Publication date: 10–16 June 2017
      Source:The Lancet, Volume 389, Issue 10086
      Author(s): The Lancet


      PubDate: 2017-06-13T23:39:00Z
       
  • When childhood is stolen
    • Authors: Lancet
      Abstract: Publication date: 10–16 June 2017
      Source:The Lancet, Volume 389, Issue 10086
      Author(s): The Lancet


      PubDate: 2017-06-13T23:39:00Z
       
  • Time to talk about menstruation: #PeriodEmoji
    • Authors: Lancet
      Abstract: Publication date: 10–16 June 2017
      Source:The Lancet, Volume 389, Issue 10086
      Author(s): The Lancet


      PubDate: 2017-06-13T23:39:00Z
       
  • Data sharing statements for clinical trials: a requirement of the
           International Committee of Medical Journal Editors
    • Authors: Darren Taichman; Peush Sahni Anja Pinborg Larry Peiperl Christine Laine
      Abstract: Publication date: Available online 6 June 2017
      Source:The Lancet
      Author(s): Darren B Taichman, Peush Sahni, Anja Pinborg, Larry Peiperl, Christine Laine, Astrid James, Sung-Tae Hong, Abraham Haileamlak, Laragh Gollogly, Fiona Godlee, Frank A Frizelle, Fernando Florenzano, Jeffrey M Drazen, Howard Bauchner, Christopher Baethge, Joyce Backus


      PubDate: 2017-06-08T21:54:06Z
       
  • Renewed push to strengthen vector control globally
    • Authors: Pedro Alonso; Dirk Engels; John Reeder
      Abstract: Publication date: Available online 1 June 2017
      Source:The Lancet
      Author(s): Pedro Alonso, Dirk Engels, John Reeder


      PubDate: 2017-06-04T14:57:11Z
      DOI: 10.1016/s0140-6736(17)31376-4
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016